Organogenesis Holdings Inc. operates as a leading regenerative medicine company focused on the development, manufacture, and commercialization of advanced medical products for the wound care and surgical markets. The company specializes in creating bio-active wound healing solutions, cellular and tissue-based products, and advanced skin substitutes derived from human donor tissues. These medical products are engineered to treat difficult, chronic wounds such as diabetic foot ulcers and venous leg ulcers, as well as complex surgical and acute wounds, helping accelerate natural tissue regeneration and clinical healing outcomes.